What is it?
A GLP-1 receptor agonist used in several FDA-approved prescription products
Peptide Library · checked July 16, 2026
Semaglutide
Semaglutide has what most entries in this Library do not: FDA-approved products and large randomized human trials. The catch is identity. Evidence for Wegovy, Ozempic, or Rybelsus does not automatically transfer to every vial carrying the ingredient name.
EstablishedReplicated relevant human evidence, or approved labeling for the exact use.How labels work →
TL;DR
The lowdown
Four answers first. The source record follows.
What do humans show?
Large randomized trials for specific products and uses—the strongest evidence class in this Library
Where does FDA stand?
Approved in specific formulations and uses; unapproved versions are not FDA-approved
What is known—and not?
FDA labeling contains a boxed warning about thyroid C-cell tumors observed in rodents; what that means in humans is unknown. The label also covers gastrointestinal adverse reactions and other important warnings and contraindications. Those are established product-level warnings, not a personalized risk assessment.
U.S. status · July 16, 2026
Approval, compounding, product, sport.
- FDA approval
- FDA-approved in specific branded formulations and indications; unapproved products are not equivalent
- U.S. federal record
- FDA-approved in specific branded formulations and indications; unapproved products are not equivalent
- Product identity
- Reviewed named-product record: Wegovy, Ozempic, Rybelsus.
- Sport
- No WADA status recorded in the reviewed source.
This reports the dated federal and sport record. It does not determine whether a particular product or transaction complies with state or federal law, and it is not legal advice.
01
What it is
Semaglutide is a GLP-1 receptor agonist in several FDA-approved prescription drugs. This is an ingredient with strong human evidence—and a product-identity problem. Product name, formulation, route, strength, and approved indication all matter. “Contains semaglutide” does not establish that an unapproved product has the quality, performance, or evidence of an FDA-approved drug.
02
What humans actually show
- Weight management: STEP 1 randomized 1,961 adults with overweight or obesity and without diabetes. At 68 weeks, average weight change was substantially greater with once-weekly semaglutide 2.4 mg plus lifestyle intervention than with placebo plus lifestyle intervention. This reports what the trial examined; it is not a dosing instruction. It is large human evidence on an identified product, not a guess from animal data.
- Cardiovascular outcomes: FDA's 2024 cardiovascular indication rested on a double-blind trial of more than 17,600 adults with established cardiovascular disease and overweight or obesity. Major cardiovascular events occurred in 6.5% of the Wegovy group and 8% of the placebo group.
- What the evidence does not do: A trial of an identified manufactured drug does not verify an unrelated product's identity, sterility, concentration, or clinical performance. Same ingredient name is not same evidence package.
03
FDA and U.S. status
Current FDA labeling includes Wegovy injection and tablets for specified weight-management and cardiovascular-risk-reduction uses. The injection label also has an accelerated-approval indication for certain adults with noncirrhotic MASH and moderate-to-advanced fibrosis. Other semaglutide brands carry different indications. Approval follows the product and use; it is not a halo around the ingredient name.
PepCurrent does not turn one product's approval into blanket approval for every formulation carrying semaglutide on the label.
04
Risks and warning limits
FDA labeling contains a boxed warning about thyroid C-cell tumors observed in rodents; what that means in humans is unknown. The label also covers gastrointestinal adverse reactions and other important warnings and contraindications. Those are established product-level warnings, not a personalized risk assessment.
PepCurrent does not provide dosing, sourcing, switching, or personalized treatment advice.
05
What would change this answer
- Label changes and new FDA-approved indications
- Enforcement involving unapproved GLP-1 products
- Evidence on long-term outcomes and treatment discontinuation
- Clear consumer communication about product and formulation identity
06
Sources and records
- FDA-approved Wegovy prescribing information, 2026
- FDA cardiovascular-risk-reduction approval announcement, 2024
- Wilding et al., 2021 — STEP 1 randomized trial
Educational journalism only; not medical advice. We do not evaluate individual products or link vendors.
What changed
Added the source-verified Claim Check to the structured claim/source/change registry.
What would change our answer
A well-controlled human study tied to the exact product, population, route, and claimed outcome could change the answer. Mechanism, anecdotes, or a different product cannot substitute for that evidence.
Version history · 1 entry
- v1 · 2026-07-16Initial structured record created from the reviewed Claim Check.Source ↗
Boundary: PepCurrent explains public evidence and regulatory records. We do not evaluate individual products, recommend use, name vendors, or provide protocols.